The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KYTX | +28.27% | N/A | N/A | -78% |
| S&P | +14.5% | +93.32% | +14.09% | +34% |
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.52M | 2.8% |
| Market Cap | $132.68M | -59.0% |
| Market Cap / Employee | $1.03M | 0.0% |
| Employees | 129 | 0.0% |
| Net Income | -$42.08M | -46.1% |
| EBITDA | -$43.90M | -33.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $53.44M | -59.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.34M | -61.8% |
| Short Term Debt | $3.58M | -7.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -53.83% | 0.0% |
| Return On Invested Capital | -61.98% | 5.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$32.15M | -27.6% |
| Operating Free Cash Flow | -$31.95M | -32.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.63 | 0.53 | 0.31 | 0.59 | -33.88% |
| Price to Tangible Book Value | 0.63 | 0.53 | 0.31 | 0.59 | -33.88% |
| Enterprise Value to EBITDA | 2.65 | 2.87 | 3.25 | 1.66 | 333.39% |
| Return on Equity | -80.7% | -49.7% | -61.3% | - | |
| Total Debt | $9.14M | $8.24M | $6.94M | $5.92M | -40.81% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
